Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

AUGUSTO E FOCIL

Allopathic & Osteopathic Physicians Family Medicine

NPI
1407906027
CMS profile
336597
Location
OXNARD, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2023 · Entire year

$246.04

11 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2023 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $246.04 11

By paying entity

PY2023 · entire year · sorted by reported total

Page 1 of 1; records 1–11 of 11 matching records. This page contains 11 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

AUGUSTO E FOCIL

NPI 1407906027 · CMS profile ID 336597

Allopathic & Osteopathic Physicians / Family Medicine

OXNARD, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–11 of 11 matching records. This page contains 11 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1407906027?year=2023&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
AUGUSTO E FOCIL, NPI 1407906027, CMS profile ID 336597. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–11 of 11 matching records. This page contains 11 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1407906027?year=2023&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
APA 7
IndustryPayments. (2026). AUGUSTO E FOCIL, NPI 1407906027, CMS profile ID 336597. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–11 of 11 matching records. This page contains 11 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1407906027?year=2023&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
Bluebook
AUGUSTO E FOCIL, NPI 1407906027, CMS profile ID 336597, IndustryPayments, General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–11 of 11 matching records. This page contains 11 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9. https://industrypayments.org/provider/npi-1407906027?year=2023&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2023 · Physicians and non-physician practitioners · CMS publication 2026-06-30

11 matching records · $246.04 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 11 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–11 of 11.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
AstraZeneca Pharmaceuticals LP $17.5112/11/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1014968725 CMS
AstraZeneca Pharmaceuticals LP $14.1711/21/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1014508521 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $29.3511/14/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 997009485 CMS
AstraZeneca Pharmaceuticals LP $0.9710/20/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1015039569 CMS
AstraZeneca Pharmaceuticals LP $27.1810/20/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1016149193 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $33.5610/19/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 997009487 CMS
AstraZeneca Pharmaceuticals LP $23.5910/13/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1015718735 CMS
AstraZeneca Pharmaceuticals LP $31.4208/09/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1011840441 CMS
AstraZeneca Pharmaceuticals LP $23.7606/13/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1011629449 CMS
Novartis Pharmaceuticals Corporation $16.7104/05/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 991705109 CMS
AstraZeneca Pharmaceuticals LP $27.8204/03/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1011939271 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $1,005.14 67
PY2020 $147.59 10
PY2021 $845.82 44
PY2022 $3,925.76 37
PY2023 $246.04 11
PY2024 $245.24 11
PY2025 $50.47 2

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $1,708,235.50 545
PY2024 Principal investigator $1,326,172.95 90
PY2023 Principal investigator $2,591,514.80 142
PY2022 Principal investigator $1,448,426.62 96
PY2021 Recipient $668.48 1
PY2021 Principal investigator $1,836,497.66 79
PY2020 Principal investigator $3,489,260.26 87
PY2019 Principal investigator $210,837.51 13

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

90 records in PY2024

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Merck Sharp & Dohme LLC $22,862.79 12/31/2024 Non-covered Recipient Entity
FOMAT Medical Research
A Phase 3, Randomized, Placebo-Controlled, Double Blind Clinical Study to Evaluate the Efficacy and Safety of Molnupiravir MK-4482 in Non-Hospitalized Adults with COVID-19 at High Risk for Disease Progression No dispute reported 06/30/2026 1136419343
Principal investigator 1 Merck Sharp & Dohme LLC $5,185.28 12/31/2024 Non-covered Recipient Entity
FOMAT Medical Research
A Phase 3, Randomized, Placebo-Controlled, Double Blind Clinical Study to Evaluate the Efficacy and Safety of Molnupiravir MK-4482 in Non-Hospitalized Adults with COVID-19 at High Risk for Disease Progression No dispute reported 06/30/2026 1136419347
Principal investigator 1 Bavarian Nordic A/S $3,577.50 12/20/2024 Non-covered Recipient Entity
FOMAT MEDICAL RESEARCH INC
ABNCoV2 Vaccine in Adult Subjects Previously Vaccinated for SARS-CoV-2 No dispute reported 06/30/2026 1119662546
Principal investigator 1 ModernaTX, Inc. $618.05 12/20/2024 Non-covered Recipient Entity
Carey Chronis MD Pediatric, Infant and Adolescent Medicine - FOMAT - HyperCore - PPDS
A Phase 1, Randomized, Observer-Blind, Placebo-Controlled, Dose-Ranging Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 12- to 30-year-old Healthy Adolescents and Adults No dispute reported 06/30/2026 1147157375
Principal investigator 1 Boehringer Ingelheim International GmbH $654.36 12/18/2024 Non-covered Recipient Entity
Fomat Medical Research
BI 456906 in NASH F2/F3 - pivotal trial No dispute reported 06/30/2026 1101073485
Principal investigator 1 PFIZER INC. $853.20 12/18/2024 Non-covered Recipient Entity
FOMAT Medical Research
AN INTERVENTIONAL EFFICACY AND SAFETY PHASE 3 DOUBLEBLIND 2ARM STUDY TO INVESTIGATE ORALLY ADMINISTERED IBUZATRELVIR COMPARED WITH PLACEBO IN NONHOSPITALIZED SYMPTOMATIC ADULT AND ADOLESCENT PARTICIPANTS WITH COVID19 WHO ARE AT HIGH RISK OF PROGRESSING TO SEVERE ILLNESS No dispute reported 06/30/2026 1130918734
Principal investigator 1 Merck Sharp & Dohme LLC $16,500.00 12/12/2024 Non-covered Recipient Entity
FOMAT Medical Research
A Phase 3, Randomized, Placebo-Controlled, Double Blind Clinical Study to Evaluate the Efficacy and Safety of Molnupiravir MK-4482 in Non-Hospitalized Adults with COVID-19 at High Risk for Disease Progression No dispute reported 06/30/2026 1136419339
Principal investigator 1 Boehringer Ingelheim International GmbH $20,000.00 11/27/2024 Non-covered Recipient Entity
Fomat Medical Research
BI 456906 in NASH F2/F3 - pivotal trial No dispute reported 06/30/2026 1101073483
Principal investigator 1 Boehringer Ingelheim International GmbH $20,000.00 11/27/2024 Non-covered Recipient Entity
Fomat Medical Research
BI 456906 in NASH F4 - pivotal trial No dispute reported 06/30/2026 1101073487
Principal investigator 1 ModernaTX, Inc. $2,347.39 11/20/2024 Non-covered Recipient Entity
Carey Chronis MD Pediatric, Infant and Adolescent Medicine - FOMAT - HyperCore - PPDS
A Phase 1, Randomized, Observer-Blind, Placebo-Controlled, Dose-Ranging Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 12- to 30-year-old Healthy Adolescents and Adults No dispute reported 06/30/2026 1147157357
Principal investigator 1 ModernaTX, Inc. $1,787.25 11/20/2024 Non-covered Recipient Entity
Carey Chronis MD Pediatric, Infant and Adolescent Medicine - FOMAT - HyperCore - PPDS
A Phase 1, Randomized, Observer-Blind, Placebo-Controlled, Dose-Ranging Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 12- to 30-year-old Healthy Adolescents and Adults No dispute reported 06/30/2026 1147157363
Principal investigator 1 ModernaTX, Inc. $1,038.32 11/20/2024 Non-covered Recipient Entity
Carey Chronis MD Pediatric, Infant and Adolescent Medicine - FOMAT - HyperCore - PPDS
A Phase 1, Randomized, Observer-Blind, Placebo-Controlled, Dose-Ranging Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 12- to 30-year-old Healthy Adolescents and Adults No dispute reported 06/30/2026 1147157367
Principal investigator 1 ModernaTX, Inc. $1,000.00 11/20/2024 Non-covered Recipient Entity
Carey Chronis MD Pediatric, Infant and Adolescent Medicine - FOMAT - HyperCore - PPDS
A Phase 1, Randomized, Observer-Blind, Placebo-Controlled, Dose-Ranging Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 12- to 30-year-old Healthy Adolescents and Adults No dispute reported 06/30/2026 1147157369
Principal investigator 1 ModernaTX, Inc. $12,820.22 11/20/2024 Non-covered Recipient Entity
Carey Chronis MD Pediatric, Infant and Adolescent Medicine - FOMAT - HyperCore - PPDS
A Phase 2/3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus (RSV), in Adults 60 Years of Age No dispute reported 06/30/2026 1147157371
Principal investigator 1 ModernaTX, Inc. $550.00 11/08/2024 Non-covered Recipient Entity
Carey Chronis MD Pediatric, Infant and Adolescent Medicine - FOMAT - HyperCore - PPDS
A Phase 2/3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus (RSV), in Adults 60 Years of Age No dispute reported 06/30/2026 1147157373
Principal investigator 1 ModernaTX, Inc. $496.78 11/01/2024 Non-covered Recipient Entity
Carey Chronis MD Pediatric, Infant and Adolescent Medicine - FOMAT - HyperCore - PPDS
A Phase 1, Randomized, Observer-Blind, Placebo-Controlled, Dose-Ranging Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 12- to 30-year-old Healthy Adolescents and Adults No dispute reported 06/30/2026 1147157359
Principal investigator 1 ModernaTX, Inc. $838.57 11/01/2024 Non-covered Recipient Entity
Carey Chronis MD Pediatric, Infant and Adolescent Medicine - FOMAT - HyperCore - PPDS
A Phase 1, Randomized, Observer-Blind, Placebo-Controlled, Dose-Ranging Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 12- to 30-year-old Healthy Adolescents and Adults No dispute reported 06/30/2026 1147157361
Principal investigator 1 ModernaTX, Inc. $968.98 11/01/2024 Non-covered Recipient Entity
Carey Chronis MD Pediatric, Infant and Adolescent Medicine - FOMAT - HyperCore - PPDS
A Phase 1, Randomized, Observer-Blind, Placebo-Controlled, Dose-Ranging Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 12- to 30-year-old Healthy Adolescents and Adults No dispute reported 06/30/2026 1147157365
Principal investigator 1 ModernaTX, Inc. $550.00 10/25/2024 Non-covered Recipient Entity
Carey Chronis MD Pediatric, Infant and Adolescent Medicine - FOMAT - HyperCore - PPDS
A Phase 2/3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus (RSV), in Adults 60 Years of Age No dispute reported 06/30/2026 1147157355
Principal investigator 1 ModernaTX, Inc. $32,373.00 10/23/2024 Non-covered Recipient Entity
Carey Chronis MD Pediatric, Infant and Adolescent Medicine - FOMAT - HyperCore - PPDS
A Phase 2/3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus (RSV), in Adults 60 Years of Age No dispute reported 06/30/2026 1147157353
Principal investigator 1 ModernaTX, Inc. $28,141.05 10/16/2024 Non-covered Recipient Entity
Carey Chronis MD Pediatric, Infant and Adolescent Medicine - FOMAT - HyperCore - PPDS
A Phase 2/3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus (RSV), in Adults 60 Years of Age No dispute reported 06/30/2026 1147157351
Principal investigator 1 PFIZER INC. $500.00 10/08/2024 Non-covered Recipient Entity
FOMAT Medical Research Inc
AN INTERVENTIONAL PHASE 23 ADAPTIVE MULTICENTER RANDOMIZED DOUBLEBLIND STUDY TO INVESTIGATE EFFICACY AND SAFETY OF ORAL SISUNATOVIR COMPARED WITH PLACEBO IN NONHOSPITALIZED SYMPTOMATIC ADULTS WITH RESPIRATORY SYNCYTIAL VIRUS INFECTION WHO ARE AT RISK OF PROGRESSION TO SEVERE ILLNESS No dispute reported 06/30/2026 1130999425
Principal investigator 1 ModernaTX, Inc. $69,109.00 09/25/2024 Non-covered Recipient Entity
Carey Chronis MD Pediatric, Infant and Adolescent Medicine - FOMAT - HyperCore - PPDS
A Phase 2/3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus (RSV), in Adults 60 Years of Age No dispute reported 06/30/2026 1147157347
Principal investigator 1 Amgen Inc. $40,270.00 09/24/2024 Non-covered Recipient Entity
FOMAT MEDICAL RESEARCH
A Ph1 Study of CB1 Antagonism in Obesity No dispute reported 06/30/2026 1096308539
Principal investigator 1 ModernaTX, Inc. $550.00 09/18/2024 Non-covered Recipient Entity
Carey Chronis MD Pediatric, Infant and Adolescent Medicine - FOMAT - HyperCore - PPDS
A Phase 2/3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus (RSV), in Adults 60 Years of Age No dispute reported 06/30/2026 1147157349
Principal investigator 1 ModernaTX, Inc. $546.48 08/16/2024 Non-covered Recipient Entity
Carey Chronis MD Pediatric, Infant and Adolescent Medicine - FOMAT - HyperCore - PPDS
A Phase 1, Randomized, Observer-Blind, Placebo-Controlled, Dose-Ranging Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 12- to 30-year-old Healthy Adolescents and Adults No dispute reported 06/30/2026 1147157329
Principal investigator 1 ModernaTX, Inc. $949.82 08/16/2024 Non-covered Recipient Entity
Carey Chronis MD Pediatric, Infant and Adolescent Medicine - FOMAT - HyperCore - PPDS
A Phase 1, Randomized, Observer-Blind, Placebo-Controlled, Dose-Ranging Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 12- to 30-year-old Healthy Adolescents and Adults No dispute reported 06/30/2026 1147157337
Principal investigator 1 ModernaTX, Inc. $58,689.47 08/14/2024 Non-covered Recipient Entity
Carey Chronis MD Pediatric, Infant and Adolescent Medicine - FOMAT - HyperCore - PPDS
A Phase 2/3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus (RSV), in Adults 60 Years of Age No dispute reported 06/30/2026 1147157339
Principal investigator 1 ModernaTX, Inc. $550.00 08/14/2024 Non-covered Recipient Entity
Carey Chronis MD Pediatric, Infant and Adolescent Medicine - FOMAT - HyperCore - PPDS
A Phase 2/3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus (RSV), in Adults 60 Years of Age No dispute reported 06/30/2026 1147157341
Principal investigator 1 Amgen Inc. $18,671.08 08/02/2024 Non-covered Recipient Entity
FOMAT MEDICAL RESEARCH
A Ph1 Study of CB1 Antagonism in Obesity No dispute reported 06/30/2026 1096308541
Principal investigator 1 ModernaTX, Inc. $4,601.28 08/01/2024 Non-covered Recipient Entity
Carey Chronis MD Pediatric, Infant and Adolescent Medicine - FOMAT - HyperCore - PPDS
A Phase 1, Randomized, Observer-Blind, Placebo-Controlled, Dose-Ranging Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 12- to 30-year-old Healthy Adolescents and Adults No dispute reported 06/30/2026 1147157327
Principal investigator 1 ModernaTX, Inc. $1,600.87 08/01/2024 Non-covered Recipient Entity
Carey Chronis MD Pediatric, Infant and Adolescent Medicine - FOMAT - HyperCore - PPDS
A Phase 1, Randomized, Observer-Blind, Placebo-Controlled, Dose-Ranging Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 12- to 30-year-old Healthy Adolescents and Adults No dispute reported 06/30/2026 1147157331
Principal investigator 1 ModernaTX, Inc. $603.16 08/01/2024 Non-covered Recipient Entity
Carey Chronis MD Pediatric, Infant and Adolescent Medicine - FOMAT - HyperCore - PPDS
A Phase 1, Randomized, Observer-Blind, Placebo-Controlled, Dose-Ranging Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 12- to 30-year-old Healthy Adolescents and Adults No dispute reported 06/30/2026 1147157333
Principal investigator 1 ModernaTX, Inc. $772.63 08/01/2024 Non-covered Recipient Entity
Carey Chronis MD Pediatric, Infant and Adolescent Medicine - FOMAT - HyperCore - PPDS
A Phase 1, Randomized, Observer-Blind, Placebo-Controlled, Dose-Ranging Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 12- to 30-year-old Healthy Adolescents and Adults No dispute reported 06/30/2026 1147157335
Principal investigator 1 ModernaTX, Inc. $908.56 07/26/2024 Non-covered Recipient Entity
Carey Chronis MD Pediatric, Infant and Adolescent Medicine - FOMAT - HyperCore - PPDS
A Phase 1, Randomized, Observer-Blind, Placebo-Controlled, Dose-Ranging Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 12- to 30-year-old Healthy Adolescents and Adults No dispute reported 06/30/2026 1147157305
Principal investigator 1 PFIZER INC. $3,725.10 07/24/2024 Non-covered Recipient Entity
FOMAT Medical Research Inc
AN INTERVENTIONAL PHASE 23 ADAPTIVE MULTICENTER RANDOMIZED DOUBLEBLIND STUDY TO INVESTIGATE EFFICACY AND SAFETY OF ORAL SISUNATOVIR COMPARED WITH PLACEBO IN NONHOSPITALIZED SYMPTOMATIC ADULTS WITH RESPIRATORY SYNCYTIAL VIRUS INFECTION WHO ARE AT RISK OF PROGRESSION TO SEVERE ILLNESS No dispute reported 06/30/2026 1131040039
Principal investigator 1 ModernaTX, Inc. $2,000.00 07/17/2024 Non-covered Recipient Entity
Carey Chronis MD Pediatric, Infant and Adolescent Medicine - FOMAT - HyperCore - PPDS
A Phase 2/3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus (RSV), in Adults 60 Years of Age No dispute reported 06/30/2026 1147157307
Principal investigator 1 ModernaTX, Inc. $92,060.35 07/17/2024 Non-covered Recipient Entity
Carey Chronis MD Pediatric, Infant and Adolescent Medicine - FOMAT - HyperCore - PPDS
A Phase 2/3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus (RSV), in Adults 60 Years of Age No dispute reported 06/30/2026 1147157309
Principal investigator 1 ModernaTX, Inc. $550.00 07/10/2024 Non-covered Recipient Entity
Carey Chronis MD Pediatric, Infant and Adolescent Medicine - FOMAT - HyperCore - PPDS
A Phase 2/3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus (RSV), in Adults 60 Years of Age No dispute reported 06/30/2026 1147157313
Principal investigator 1 ModernaTX, Inc. $550.00 07/10/2024 Non-covered Recipient Entity
Carey Chronis MD Pediatric, Infant and Adolescent Medicine - FOMAT - HyperCore - PPDS
A Phase 2/3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus (RSV), in Adults 60 Years of Age No dispute reported 06/30/2026 1147157315
Principal investigator 1 ModernaTX, Inc. $550.00 07/01/2024 Non-covered Recipient Entity
Carey Chronis MD Pediatric, Infant and Adolescent Medicine - FOMAT - HyperCore - PPDS
A Phase 2/3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus (RSV), in Adults 60 Years of Age No dispute reported 06/30/2026 1147157311
Principal investigator 1 PFIZER INC. $4,000.00 06/26/2024 Non-covered Recipient Entity
FOMAT Medical Research Inc
AN INTERVENTIONAL PHASE 23 ADAPTIVE MULTICENTER RANDOMIZED DOUBLEBLIND STUDY TO INVESTIGATE EFFICACY AND SAFETY OF ORAL SISUNATOVIR COMPARED WITH PLACEBO IN NONHOSPITALIZED SYMPTOMATIC ADULTS WITH RESPIRATORY SYNCYTIAL VIRUS INFECTION WHO ARE AT RISK OF PROGRESSION TO SEVERE ILLNESS No dispute reported 06/30/2026 1131055208
Principal investigator 1 ModernaTX, Inc. $750.00 06/20/2024 Non-covered Recipient Entity
Carey Chronis MD Pediatric, Infant and Adolescent Medicine - FOMAT - HyperCore - PPDS
A Phase 1, Randomized, Observer-Blind, Placebo-Controlled, Dose-Ranging Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 12- to 30-year-old Healthy Adolescents and Adults No dispute reported 06/30/2026 1147157301
Principal investigator 1 ModernaTX, Inc. $76,335.85 06/12/2024 Non-covered Recipient Entity
Carey Chronis MD Pediatric, Infant and Adolescent Medicine - FOMAT - HyperCore - PPDS
A Phase 2/3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus (RSV), in Adults 60 Years of Age No dispute reported 06/30/2026 1147157303
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $471.43 05/22/2024 Non-covered Recipient Entity
Fomat Medical Research Incorporated
A Study of Experimental Medication BMS-986036 in Adults With Nonalcoholic Steatohepatitis (NASH) and Stage 3 Liver Fibrosis (FALCON 1) No dispute reported 06/30/2026 1123477298
Principal investigator 1 ModernaTX, Inc. $330.00 05/22/2024 Non-covered Recipient Entity
Carey Chronis MD Pediatric, Infant and Adolescent Medicine - FOMAT - HyperCore - PPDS
A Phase 2/3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus (RSV), in Adults 60 Years of Age No dispute reported 06/30/2026 1147157297
Principal investigator 1 ModernaTX, Inc. $146,119.95 05/17/2024 Non-covered Recipient Entity
Carey Chronis MD Pediatric, Infant and Adolescent Medicine - FOMAT - HyperCore - PPDS
A Phase 2/3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus (RSV), in Adults 60 Years of Age No dispute reported 06/30/2026 1147157295
Principal investigator 1 ModernaTX, Inc. $5,481.37 05/01/2024 Non-covered Recipient Entity
Carey Chronis MD Pediatric, Infant and Adolescent Medicine - FOMAT - HyperCore - PPDS
A Phase 1, Randomized, Observer-Blind, Placebo-Controlled, Dose-Ranging Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 12- to 30-year-old Healthy Adolescents and Adults No dispute reported 06/30/2026 1147157289
Principal investigator 1 ModernaTX, Inc. $1,000.00 05/01/2024 Non-covered Recipient Entity
Carey Chronis MD Pediatric, Infant and Adolescent Medicine - FOMAT - HyperCore - PPDS
A Phase 1, Randomized, Observer-Blind, Placebo-Controlled, Dose-Ranging Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 12- to 30-year-old Healthy Adolescents and Adults No dispute reported 06/30/2026 1147157291
Principal investigator 1 ModernaTX, Inc. $86.26 05/01/2024 Non-covered Recipient Entity
Carey Chronis MD Pediatric, Infant and Adolescent Medicine - FOMAT - HyperCore - PPDS
A Phase 1, Randomized, Observer-Blind, Placebo-Controlled, Dose-Ranging Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 12- to 30-year-old Healthy Adolescents and Adults No dispute reported 06/30/2026 1147157293
Principal investigator 1 ModernaTX, Inc. $550.00 05/01/2024 Non-covered Recipient Entity
Carey Chronis MD Pediatric, Infant and Adolescent Medicine - FOMAT - HyperCore - PPDS
A Phase 2/3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus (RSV), in Adults 60 Years of Age No dispute reported 06/30/2026 1147157299
Principal investigator 1 ModernaTX, Inc. $68,566.05 04/10/2024 Non-covered Recipient Entity
Carey Chronis MD Pediatric, Infant and Adolescent Medicine - FOMAT - HyperCore - PPDS
A Phase 2/3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus (RSV), in Adults 60 Years of Age No dispute reported 06/30/2026 1147157283
Principal investigator 1 ModernaTX, Inc. $976.36 04/05/2024 Non-covered Recipient Entity
Carey Chronis MD Pediatric, Infant and Adolescent Medicine - FOMAT - HyperCore - PPDS
A Phase 1, Randomized, Observer-Blind, Placebo-Controlled, Dose-Ranging Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 12- to 30-year-old Healthy Adolescents and Adults No dispute reported 06/30/2026 1147157277
Principal investigator 1 ModernaTX, Inc. $4,900.00 04/05/2024 Non-covered Recipient Entity
Carey Chronis MD Pediatric, Infant and Adolescent Medicine - FOMAT - HyperCore - PPDS
A Phase 1, Randomized, Observer-Blind, Placebo-Controlled, Dose-Ranging Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 12- to 30-year-old Healthy Adolescents and Adults No dispute reported 06/30/2026 1147157279
Principal investigator 1 ModernaTX, Inc. $1,455.15 04/05/2024 Non-covered Recipient Entity
Carey Chronis MD Pediatric, Infant and Adolescent Medicine - FOMAT - HyperCore - PPDS
A Phase 1, Randomized, Observer-Blind, Placebo-Controlled, Dose-Ranging Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 12- to 30-year-old Healthy Adolescents and Adults No dispute reported 06/30/2026 1147157281
Principal investigator 1 Bavarian Nordic A/S $1,341.36 04/03/2024 Non-covered Recipient Entity
FOMAT MEDICAL RESEARCH INC
ABNCoV2 Vaccine in Adult Subjects Previously Vaccinated for SARS-CoV-2 No dispute reported 06/30/2026 1119662540
Principal investigator 1 Bavarian Nordic A/S $121.50 04/03/2024 Non-covered Recipient Entity
FOMAT MEDICAL RESEARCH INC
ABNCoV2 Vaccine in Adult Subjects Previously Vaccinated for SARS-CoV-2 No dispute reported 06/30/2026 1119662542
Principal investigator 1 Bavarian Nordic A/S $8,721.00 04/03/2024 Non-covered Recipient Entity
FOMAT MEDICAL RESEARCH INC
ABNCoV2 Vaccine in Adult Subjects Previously Vaccinated for SARS-CoV-2 No dispute reported 06/30/2026 1119662544
Principal investigator 1 ModernaTX, Inc. $155,013.85 03/15/2024 Non-covered Recipient Entity
Carey Chronis MD Pediatric, Infant and Adolescent Medicine - FOMAT - HyperCore - PPDS
A Phase 2/3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus (RSV), in Adults 60 Years of Age No dispute reported 06/30/2026 1147157269
Principal investigator 1 PFIZER INC. $17,000.00 03/12/2024 Non-covered Recipient Entity
FOMAT Medical Research Inc
AN INTERVENTIONAL PHASE 23 ADAPTIVE MULTICENTER RANDOMIZED DOUBLEBLIND STUDY TO INVESTIGATE EFFICACY AND SAFETY OF ORAL SISUNATOVIR COMPARED WITH PLACEBO IN NONHOSPITALIZED SYMPTOMATIC ADULTS WITH RESPIRATORY SYNCYTIAL VIRUS INFECTION WHO ARE AT RISK OF PROGRESSION TO SEVERE ILLNESS No dispute reported 06/30/2026 1131085583
Principal investigator 1 ModernaTX, Inc. $550.00 03/08/2024 Non-covered Recipient Entity
Carey Chronis MD Pediatric, Infant and Adolescent Medicine - FOMAT - HyperCore - PPDS
A Phase 2/3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus (RSV), in Adults 60 Years of Age No dispute reported 06/30/2026 1147157271
Principal investigator 1 ModernaTX, Inc. $1,629.41 02/28/2024 Non-covered Recipient Entity
Carey Chronis MD Pediatric, Infant and Adolescent Medicine - FOMAT - HyperCore - PPDS
A Phase 1, Randomized, Observer-Blind, Placebo-Controlled, Dose-Ranging Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 12- to 30-year-old Healthy Adolescents and Adults No dispute reported 06/30/2026 1147157263
Principal investigator 1 ModernaTX, Inc. $2,295.95 02/28/2024 Non-covered Recipient Entity
Carey Chronis MD Pediatric, Infant and Adolescent Medicine - FOMAT - HyperCore - PPDS
A Phase 1, Randomized, Observer-Blind, Placebo-Controlled, Dose-Ranging Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 12- to 30-year-old Healthy Adolescents and Adults No dispute reported 06/30/2026 1147157265
Principal investigator 1 ModernaTX, Inc. $5,058.41 02/28/2024 Non-covered Recipient Entity
Carey Chronis MD Pediatric, Infant and Adolescent Medicine - FOMAT - HyperCore - PPDS
A Phase 1, Randomized, Observer-Blind, Placebo-Controlled, Dose-Ranging Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 12- to 30-year-old Healthy Adolescents and Adults No dispute reported 06/30/2026 1147157267
Principal investigator 1 Eli Lilly and Company $622.96 02/26/2024 Non-covered Recipient Entity
FOMAT MEDICAL RESEARCH INC
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF TIRZEPATIDE ON THE REDUCTION OF MORBIDITY AND MORTALITY IN ADULTS WITH OBESITY No dispute reported 06/30/2026 1137358083
Principal investigator 1 ModernaTX, Inc. $550.00 02/23/2024 Non-covered Recipient Entity
Carey Chronis MD Pediatric, Infant and Adolescent Medicine - FOMAT - HyperCore - PPDS
A Phase 2/3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus (RSV), in Adults 60 Years of Age No dispute reported 06/30/2026 1147157253
Principal investigator 1 ModernaTX, Inc. $19,884.15 02/23/2024 Non-covered Recipient Entity
Carey Chronis MD Pediatric, Infant and Adolescent Medicine - FOMAT - HyperCore - PPDS
A Phase 2/3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus (RSV), in Adults 60 Years of Age No dispute reported 06/30/2026 1147157255
Principal investigator 1 PFIZER INC. $1,000.00 02/19/2024 Non-covered Recipient Entity
FOMAT MEDICAL RESEARCH
AN INTERVENTIONAL PHASE 23 ADAPTIVE MULTICENTER RANDOMIZED DOUBLEBLIND STUDY TO INVESTIGATE EFFICACY AND SAFETY OF ORAL SISUNATOVIR COMPARED WITH PLACEBO IN NONHOSPITALIZED SYMPTOMATIC ADULTS WITH RESPIRATORY SYNCYTIAL VIRUS INFECTION WHO ARE AT RISK OF PROGRESSION TO SEVERE ILLNESS No dispute reported 06/30/2026 1131093136
Principal investigator 1 PFIZER INC. $6,300.00 02/19/2024 Non-covered Recipient Entity
FOMAT MEDICAL RESEARCH
AN INTERVENTIONAL PHASE 23 ADAPTIVE MULTICENTER RANDOMIZED DOUBLEBLIND STUDY TO INVESTIGATE EFFICACY AND SAFETY OF ORAL SISUNATOVIR COMPARED WITH PLACEBO IN NONHOSPITALIZED SYMPTOMATIC ADULTS WITH RESPIRATORY SYNCYTIAL VIRUS INFECTION WHO ARE AT RISK OF PROGRESSION TO SEVERE ILLNESS No dispute reported 06/30/2026 1131093142
Principal investigator 1 PFIZER INC. $150.00 02/19/2024 Non-covered Recipient Entity
FOMAT MEDICAL RESEARCH
AN INTERVENTIONAL PHASE 23 ADAPTIVE MULTICENTER RANDOMIZED DOUBLEBLIND STUDY TO INVESTIGATE EFFICACY AND SAFETY OF ORAL SISUNATOVIR COMPARED WITH PLACEBO IN NONHOSPITALIZED SYMPTOMATIC ADULTS WITH RESPIRATORY SYNCYTIAL VIRUS INFECTION WHO ARE AT RISK OF PROGRESSION TO SEVERE ILLNESS No dispute reported 06/30/2026 1131095329
Principal investigator 1 Bavarian Nordic A/S $2,000.00 02/16/2024 Non-covered Recipient Entity
FOMAT MEDICAL RESEARCH INC
ABNCoV2 Vaccine in Adult Subjects Previously Vaccinated for SARS-CoV-2 No dispute reported 06/30/2026 1119662526
Principal investigator 1 PFIZER INC. $10,900.00 02/12/2024 Non-covered Recipient Entity
FOMAT MEDICAL RESEARCH
AN INTERVENTIONAL PHASE 23 ADAPTIVE MULTICENTER RANDOMIZED DOUBLEBLIND STUDY TO INVESTIGATE EFFICACY AND SAFETY OF ORAL SISUNATOVIR COMPARED WITH PLACEBO IN NONHOSPITALIZED SYMPTOMATIC ADULTS WITH RESPIRATORY SYNCYTIAL VIRUS INFECTION WHO ARE AT RISK OF PROGRESSION TO SEVERE ILLNESS No dispute reported 06/30/2026 1131093148
Principal investigator 1 Bavarian Nordic A/S $5,000.00 02/09/2024 Non-covered Recipient Entity
FOMAT MEDICAL RESEARCH INC
ABNCoV2 Vaccine in Adult Subjects Previously Vaccinated for SARS-CoV-2 No dispute reported 06/30/2026 1119662538
Principal investigator 1 ModernaTX, Inc. $101,540.65 02/09/2024 Non-covered Recipient Entity
Carey Chronis MD Pediatric, Infant and Adolescent Medicine - FOMAT - HyperCore - PPDS
A Phase 2/3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus (RSV), in Adults 60 Years of Age No dispute reported 06/30/2026 1147157257
Principal investigator 1 ModernaTX, Inc. $1,685.32 01/24/2024 Non-covered Recipient Entity
Carey Chronis MD Pediatric, Infant and Adolescent Medicine - FOMAT - HyperCore - PPDS
A Phase 1, Randomized, Observer-Blind, Placebo-Controlled, Dose-Ranging Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 12- to 30-year-old Healthy Adolescents and Adults No dispute reported 06/30/2026 1147157247
Principal investigator 1 ModernaTX, Inc. $11,005.04 01/24/2024 Non-covered Recipient Entity
Carey Chronis MD Pediatric, Infant and Adolescent Medicine - FOMAT - HyperCore - PPDS
A Phase 1, Randomized, Observer-Blind, Placebo-Controlled, Dose-Ranging Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 12- to 30-year-old Healthy Adolescents and Adults No dispute reported 06/30/2026 1147157249
Principal investigator 1 ModernaTX, Inc. $3,020.14 01/24/2024 Non-covered Recipient Entity
Carey Chronis MD Pediatric, Infant and Adolescent Medicine - FOMAT - HyperCore - PPDS
A Phase 1, Randomized, Observer-Blind, Placebo-Controlled, Dose-Ranging Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 12- to 30-year-old Healthy Adolescents and Adults No dispute reported 06/30/2026 1147157251
Principal investigator 1 Bavarian Nordic A/S $600.00 01/19/2024 Non-covered Recipient Entity
FOMAT MEDICAL RESEARCH INC
ABNCoV2 Vaccine in Adult Subjects Previously Vaccinated for SARS-CoV-2 No dispute reported 06/30/2026 1119662532
Principal investigator 1 Bavarian Nordic A/S $2,250.00 01/19/2024 Non-covered Recipient Entity
FOMAT MEDICAL RESEARCH INC
ABNCoV2 Vaccine in Adult Subjects Previously Vaccinated for SARS-CoV-2 No dispute reported 06/30/2026 1119662534
Principal investigator 1 Alnylam Pharmaceuticals Inc. $832.00 01/12/2024 Non-covered Recipient Entity
FOMAT Medical Research
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121173627
Principal investigator 1 Bavarian Nordic A/S $1,500.00 01/12/2024 Non-covered Recipient Entity
FOMAT MEDICAL RESEARCH INC
ABNCoV2 Vaccine in Adult Subjects Previously Vaccinated for SARS-CoV-2 No dispute reported 06/30/2026 1119662530
Principal investigator 1 Bavarian Nordic A/S $2,200.00 01/12/2024 Non-covered Recipient Entity
FOMAT MEDICAL RESEARCH INC
ABNCoV2 Vaccine in Adult Subjects Previously Vaccinated for SARS-CoV-2 No dispute reported 06/30/2026 1119662536
Principal investigator 1 Bavarian Nordic A/S $1,500.00 01/12/2024 Non-covered Recipient Entity
FOMAT MEDICAL RESEARCH INC
ABNCoV2 Vaccine in Adult Subjects Previously Vaccinated for SARS-CoV-2 No dispute reported 06/30/2026 1119662548
Principal investigator 1 ModernaTX, Inc. $100,404.25 01/12/2024 Non-covered Recipient Entity
Carey Chronis MD Pediatric, Infant and Adolescent Medicine - FOMAT - HyperCore - PPDS
A Phase 2/3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus (RSV), in Adults 60 Years of Age No dispute reported 06/30/2026 1147157245
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,250.00 01/10/2024 Non-covered Recipient Entity
FOMAT Medical Research
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121173423
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,200.00 01/10/2024 Non-covered Recipient Entity
FOMAT Medical Research
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121173425
Principal investigator 1 Alnylam Pharmaceuticals Inc. $4,000.00 01/10/2024 Non-covered Recipient Entity
FOMAT Medical Research
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121173623
Principal investigator 1 Alnylam Pharmaceuticals Inc. $3,000.00 01/10/2024 Non-covered Recipient Entity
FOMAT Medical Research
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121173625
Principal investigator 1 Bavarian Nordic A/S $1,200.00 01/10/2024 Non-covered Recipient Entity
FOMAT MEDICAL RESEARCH INC
ABNCoV2 Vaccine in Adult Subjects Previously Vaccinated for SARS-CoV-2 No dispute reported 06/30/2026 1119662528
Principal investigator 1 Eli Lilly and Company $68,904.00 01/02/2024 Non-covered Recipient Entity
FOMAT MEDICAL RESEARCH INC
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF TIRZEPATIDE ON THE REDUCTION OF MORBIDITY AND MORTALITY IN ADULTS WITH OBESITY No dispute reported 06/30/2026 1137359321